ProCE Banner Activity


Role of the Pharmacist in Timely and Optimal Management of Immune-Related Adverse Events


In this on-demand webcast from a live webinar, expert faculty discuss the management of irAEs from immunotherapies used alone or in combination with VEGF inhibitors.

Pharmacists: 1.25 contact hours (0.125 CEUs)

Released: May 24, 2023

Expiration: May 23, 2024



Alexa Basilio

Alexa Basilio, PharmD, BCOP

Clinical Oncology Pharmacy Specialist 
Emory Healthcare, Winship Cancer Institute
Atlanta, Georgia 

Jordan McPherson

Jordan McPherson, PharmD, MS, BCOP

Interim Clinical Manager
Huntsman Cancer Institute
Oncology Clinical Pharmacist
Melanoma and Non-Melanoma Skin Cancers
Adjunct Associate Professor
University of Utah College of Pharmacy
Salt Lake City, Utah

Provided by

Provided by ProCE, LLC

ProCE Banner


Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Target Audience

The target audience is pharmacists, including community, outpatient, and ambulatory care pharmacists, who care for patients with and at risk for irAEs.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of pharmacists in identifying and managing irAEs to improve patient outcomes. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize the clinical efficacy and safety profiles associated with ICIs and ICI-targeted therapy combinations in various types of cancers

  • Develop a proactive management plan for early recognition and appropriate management of irAEs and associated ICI and ICI-targeted therapy combinations to support quality of life and continuation of treatment that incorporates collaboration among oncologists and physician subspecialists on the multidisciplinary cancer care team 

  • Discern between immune-related and targeted therapy–associated adverse events to identify proper management approaches

  • Apply evidence-based and guidelines-based recommendations to the management of irAEs to optimize patient care

  • Communicate effectively to engage patients and caregivers in monitoring for the potential onset of irAEs to aid self-monitoring and AE reporting


ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Alexa Basilio, PharmD, BCOP, has no relevant financial relationships to disclose.

Jordan McPherson, PharmD, MS, BCOP: researcher: Hitachi.

The planners and content peer reviewers from ProCE, LLC do not have any relevant financial relationships to disclose.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.



ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-23-009-H01-P has been assigned to this home study application-based activity. This activity is approved for 1.25 contact hours (0.125 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.